Adma Biologics (ADMA) Revenue Growth (5y) (2016 - 2025)
Adma Biologics (ADMA) Revenue Growth (5y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - |
| 3 | Akari Therapeutics | 973.81 Bn | 973.81 Bn | - |
| 4 | BeOne Medicines | 471.45 Bn | 466.66 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.00 Bn | 114.75 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.99 Bn | 61.23 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.86 Bn | 50.67 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn |
| 10 | Adma Biologics | 2.04 Bn | 1.95 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.40% |
| Sep 30, 2025 | 67.19% |
| Jun 30, 2025 | 73.37% |
| Mar 31, 2025 | 62.28% |
| Dec 31, 2024 | 57.83% |
| Sep 30, 2024 | 75.38% |
| Jun 30, 2024 | 72.59% |
| Mar 31, 2024 | 87.55% |
| Dec 31, 2023 | 78.69% |
| Sep 30, 2023 | 91.87% |
| Jun 30, 2023 | 67.06% |
| Mar 31, 2023 | 70.02% |
| Dec 31, 2022 | 32.78% |
| Sep 30, 2022 | 54.33% |
| Jun 30, 2022 | 85.67% |
| Mar 31, 2022 | 62.19% |
| Dec 31, 2021 | 75.25% |
| Sep 30, 2021 | 47.74% |
| Jun 30, 2021 | 50.99% |
| Mar 31, 2021 | 49.85% |